Browsing tag:

Major Depressive Disorder


The approval of Vortioxetine CAS# 508233-74-7 came as exciting news at the close of September 2013. Known as the brand name Brintellix, Vortioxetine is marketed by Lundbeck and Takeda Pharmaceuticals. The FDA approval of this antidepressant is encouraging for both patients suffering from Major Depressive Disorder and the practitioners who treat these patients, as Vortioxetine[…]

Read More

Levomilnacipran, CAS number 96847-55-1, has been a headline in the recent pharmaceutical news. This headline status is due to the FDA approval of Fetzima, the brand name for Levomilnacipran, at the end of July 2013. Approved as a medication to treat major depressive disorder in adults, Levomilnacipran is designed as a once daily dose. As[…]

Read More

As a blockbuster medication used to treat schizophrenia, Aripiprazole CAS# 129722-12-9 has recently been approved by the FDA as a once a month treatment. Marketed by Otsuka and Bristol-Myers Squibb, this monthly dosage of aripiprazole will be sold under the name Abilify Maintena. Aripiprazole is a solid and reliable long-acting antipsychotic medication, and this FDA[…]

Read More

Vilazodone is in a class of medications called selective serotonin reuptake inhibitors, or SSRIs, and is also a 5HT1A receptor partial agonist. Known as the brand name Viibryd, this medication was approved in January of 2011 to treat Major Depressive Disorder in adults. In safety studies involving 2,177 patients the most common adverse side effects[…]

Read More

Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year.  The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service